Mon Sep 23 16:58:48 UTC 2024: ## OPKO Health Shares Gap Down After Earnings Beat, Analyst Opinions Diverge
**New York, NY** – OPKO Health, Inc. (NASDAQ:OPK) saw its stock price drop in pre-market trading on Monday, opening at $1.45 after closing at $1.48 on Friday. The decline comes despite the company exceeding earnings expectations for the quarter ending August 7th.
OPKO reported earnings per share of ($0.01), exceeding analysts’ expectations of ($0.09) by $0.08. Revenue for the quarter reached $182.20 million, falling short of estimates at $184.70 million but down 31.3% year-over-year.
Despite the earnings beat, analyst opinions on OPKO remain divided. StockNews.com downgraded the company to a “sell” rating on July 27th, while Barrington Research maintained an “outperform” rating with a $2.25 price target. Other firms, such as HC Wainwright and Piper Sandler, hold bullish stances, reiterating “buy” and “overweight” ratings with price targets of $3.00.
Insider activity also raises questions. Opko Health, Inc. sold 14,082 shares of the company’s stock on July 3rd at an average price of $28.23, for a total transaction of $397,534.86. This sale, however, represents a small fraction of the insider’s total holdings in the company.
Institutional investor activity remains mixed. While some, such as IPG Investment Advisors LLC, have recently bought shares, others like CIBC Asset Management Inc. have increased their holdings.
OPKO Health, Inc. operates in the diagnostics and pharmaceuticals industries, primarily through its BioReference Laboratories division, which offers laboratory testing services to various healthcare providers.
Investors will be closely watching to see how the company’s stock performs in the coming weeks and months, as well as the impact of its earnings report and varying analyst opinions on its future prospects.
First Piper 